Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020540 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
A Phase 1 study of Kidney Cancer and Melanoma (Skin), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00020540: Completed Phase 1 study of Kidney Cancer and Melanoma (Skin), sponsored by National Cancer Institute (NCI).
NCT00020540 is a Phase 1 study of Kidney Cancer and Melanoma (Skin) that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020540, a Phase 1 study of Kidney Cancer and Melanoma (Skin), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. Biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. PURPOSE: Phase I trial to study the effectiveness of flt3L combined with CD40-ligand in treating patients who have metastatic melanoma or metastatic kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL recombinant CD40-ligand
- BIOLOGICAL recombinant flt3 ligand
Study Locations (1)
Maryland
- Surgery Branch - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Phase | Phase 1 |
What the finished NCT00020540 record still lists
NCT00020540 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which recombinant CD40-ligand is the first listed.
NCT00020540 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00020540 about?
NCT00020540 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer". RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. Biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. PURPOSE: Phase I trial to study the effectivenes...
What is the current status of trial NCT00020540?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-03.
What conditions does trial NCT00020540 study?
This clinical trial studies the following conditions: Kidney Cancer, Melanoma (Skin).
What interventions are being tested in trial NCT00020540?
The interventions under investigation include: recombinant CD40-ligand (BIOLOGICAL), recombinant flt3 ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020540?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020540 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study of VET3-TGI in Patients With Solid Tumors
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia